Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

247 Views

Poster Session: PK/PD Studies

609 - In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

CG

Christian M. Gill, PharmD

Associate Director, Translational Pharmacology and Microbiology Research
Hartford Hospital
Hartford, Connecticut, United States

Co-Author(s)

DS

Debora Santini, n/a

Research Technologist
Hartford Hospital
Hartford, Connecticut, United States
MT

Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd
Toyonaka, Osaka, Japan
CL

Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V.
London, England, United Kingdom
YY

Yoshinori Yamano, PhD (he/him/his)

Chief Scientific Officer for Infectious Diseases
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
RE

Roger Echols, MD

Consultant
Infectious Disease Drug Development Consulting
Easton, Connecticut, United States
DN

David P. Nicolau, PharmD

Director
Hartford Hospital
Hartford, Connecticut, United States